1. Oncogene SETDB1's dual role: driving tumor progression and immune escape. Salari K, Hao J, Jilek R, Wells M, Li T, Johnson E, Meng W, Wang H, Zibble E, Allen A, Gilbert J, McLerran R, Schuett E, Oliva C, Griguer CE, Meyerholz DK, Yates MS, Keen HL, Meng X, Xiong Y, Li B, Yang S.Oncogene. 2026 Aug 1. doi: 10.1038/s41388-026-03911-9. Online ahead of print. PMID: 42542437
  2. Essential Protein PHB2 and Its Regulatory Mechanisms in Cancer. Qi A, Lamont L, Liu E, Murray SD, Meng X, Yang S. Cells. 2023 Apr 21;12(8):1211. doi:10.3390/cells12081211. PMID: 37190120
  3. Dual PI3K and HDAC inhibitor, CUDC-907, effectively inhibits endometrial cancer growth in vitro and in vivo. Zhang X, Lazaro-Camp V, Li T, Qi A, Lan L, Lamont L, Zhao L, Meehan MR, Gardner SN, Meng W, Xiong Y, Leidinger M, Imai Y, Meng X, Yang S. Front Oncol. 2025 Nov 4;15:1531805. doi: 10.3389/fonc.2025.1531805. eCollection 2025. PMID: 41262902
  4. SETDB1: A perspective into immune cell function and cancer immunotherapy. Johnson E, Salari K, Yang S. Immunology. 2023 May;169(1):3-12. doi: 10.1111/imm.13619. Epub 2022 Dec 21. PMID: 36524435
  5. Enhancing progestin therapy via HDAC inhibitors in endometrial cancer. Li Y, Zhou W, Li L, Li JW, Li T, Huang C, Lazaro-Camp VJ, Kavlashvili T, Zhang Y, Reyes H, Li Y, Dai D, Zhu W, Meng X, Leslie KK, Yang S. Am J Cancer Res. 2022 Nov 15;12(11):5029-5048. eCollection 2022. PMID: 36504895
  6. Utilizing an Endogenous Progesterone Receptor Reporter Gene for Drug Screening and Mechanistic Study in Endometrial Cancer. Li Y, Zhou W, Meng X, Murray SD, Li L, Fronk A, Lazaro-Camp VJ, Wen KK, Wu M, Dupuy A, Leslie KK, Yang S. Cancers (Basel). 2022 Oct 6;14(19):4883. doi: 10.3390/cancers14194883. PMID: 36230806
  7. SETDB1 in cancer: overexpression and its therapeutic implications. Lazaro-Camp VJ, Salari K, Meng X, Yang S. Am J Cancer Res. 2021 May 15;11(5):1803-1827. eCollection 2021. PMID: 34094655